Clinical Trial Update: Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial [Phase 1]

View source ↗

Summary

This is an early-stage (Phase 1) clinical trial evaluating the combination of DS-8201a (trastuzumab deruxtecan) and AZD6738 (camonsertib) for HER2-expressing ad…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Carcinoma
• Colorectal Carcinoma
• Endometrial Carcinoma
• Gastric Carcinoma
• Gastroesophageal Junction Adenocarcinoma
• Malignant Hepatobiliary Neoplasm
• Salivary Gland Carcinoma

Drugs mentioned

• AZD6738 (camonsertib) (camonsertib)
• DS-8201a / trastuzumab deruxtecan (trastuzumab deruxtecan)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Advanced Breast Carcinoma, Advanced Colon Carcinoma | Phase 1 | Status: RECRUITING